Adeno-associated virus production of soluble tumor necrosis factor receptor neutralizes tumor necrosis factor alpha and reduces arthritis.
The major limitation of adenovirus is its association with induction of an inflammatory response and relatively short-term production of the gene therapy transgene product. Adeno-associated virus (AAV) is a 4.68-kb single-strand DNA virus that contains ITRs for viral replication and a packaging signal, and also has been engineered to contain therapeutic genes up to 5 kb in length. Transduction of recombinant AAV (rAAV) results in low inflammatory response and long-term expression. We have cloned a low-immunogenic form of human sTNFRI (sTNFRI2.6D) into AAV (rAAVsTNFRI). This vector was analyzed for its ability to transfect and neutralize the effect of TNF-alpha on primary rheumatoid arthritis synovial fibroblast (RASFs). The rAAVsTNFRI was transduced into the cells at 1.8 x 10(1), 1.8 x 10(2), and 1.8 x 10(3) viral particles per cell. There was greater than 90% neutralization of TNF-alpha at 1.8 x 10(3) viral particles/cell. There was a significant decrease in the synovial cell hyperplasia and cartilage and bone destruction in human TNF-alpha transgenic mice treated intraarticularly with rAAVsTNFRI. These results indicate that the low-immunogenic and long-term expressing vector, rAAVsTNFRI, can be used to deliver the soluble TNF-alpha in vitro and in vivo and effectively reduce the severity of arthritis.
Zhang
H G
HG
Division of Clinical Immunology and Rheumatology, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL 35294, USA.
Xie
J
J
Yang
P
P
Wang
Y
Y
Xu
L
L
Liu
D
D
Hsu
H C
HC
Zhou
T
T
Edwards
C K
CK
Mountz
J D
JD
D000818:Animals; D015703:Antigens, CD / Q000235:genetics* / Q000378:metabolism; D001168:Arthritis / Q000473:pathology / Q000628:therapy*; D001169:Arthritis, Experimental / Q000628:therapy; D001172:Arthritis, Rheumatoid / Q000473:pathology*; D002478:Cells, Cultured; D017364:Collagenases / Q000187:drug effects / Q000378:metabolism; D000229:Dependovirus / Q000235:genetics*; D005260:Female; D005347:Fibroblasts / Q000821:virology; D015316:Genetic Therapy / Q000379:methods*; D006801:Humans; D007739:L Cells; D051379:Mice; D008822:Mice, Transgenic; D009132:Muscles / Q000821:virology; D018124:Receptors, Tumor Necrosis Factor / Q000235:genetics* / Q000378:metabolism; D047888:Receptors, Tumor Necrosis Factor, Type I; D011994:Recombinant Proteins / Q000235:genetics / Q000378:metabolism; D013585:Synovitis / Q000473:pathology / Q000628:therapy; D018675:Toxicity Tests; D014409:Tumor Necrosis Factor-alpha / Q000378:metabolism*
D015703:Antigens, CD; D018124:Receptors, Tumor Necrosis Factor; D047888:Receptors, Tumor Necrosis Factor, Type I; D011994:Recombinant Proteins; D014409:Tumor Necrosis Factor-alpha; D017364:Collagenases